Sri Lanka

Resilience System


You are here

Disease Prevention

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.

...

 

 

 

 

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

EU’s Covid recovery fund under pressure to allocate unused funds

BRUSSELS — Governments have received less than a third of the EU's original €723 billion pot to help boost post-Covid economic recovery and are now heaping pressure on the European Commission to speed up payments.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Mpox vaccine boosters necessary to restore faded protection -- Swedish study

...

Antibody levels fell to low or near zero within the first few months of getting the vaccine, unless the person had previously received a smallpox vaccine, scientists reported Saturday at the European Congress of Clinical Microbiology and Infectious Diseases in Barcelona.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Moderna reports higher immune response for next-generation COVID vaccine

...

The mRNA-1283 vaccine showed a higher immune response—including in seniors—than its currently licensed vaccine, called mRNA-1273.222. Response was higher against Omicron BA.4/BA.5 as well as the original SARS-CoV-2 virus.

...

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Disease Prevention
howdy folks